vs
Side-by-side financial comparison of INNEOVA Holdings Ltd (INEO) and Valneva SE (VALN). Click either name above to swap in a different company.
Valneva SE is the larger business by last-quarter revenue ($36.2M vs $30.8M, roughly 1.2× INNEOVA Holdings Ltd). INNEOVA Holdings Ltd runs the higher net margin — 0.8% vs -54.1%, a 54.9% gap on every dollar of revenue.
Valneva SE is a specialty vaccine company registered in Saint-Herblain, France, developing, producing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States.
INEO vs VALN — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2023
| Metric | | |
|---|---|---|
| Revenue | $30.8M | $36.2M |
| Net Profit | $243.0K | $-19.6M |
| Gross Margin | 19.3% | 38.9% |
| Operating Margin | 3.6% | -49.5% |
| Net Margin | 0.8% | -54.1% |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $30.8M | — | ||
| Q1 23 | — | $36.2M | ||
| Q2 22 | — | $93.2M |
| Q2 25 | $243.0K | — | ||
| Q1 23 | — | $-19.6M | ||
| Q2 22 | — | — |
| Q2 25 | 19.3% | — | ||
| Q1 23 | — | 38.9% | ||
| Q2 22 | — | — |
| Q2 25 | 3.6% | — | ||
| Q1 23 | — | -49.5% | ||
| Q2 22 | — | -161.3% |
| Q2 25 | 0.8% | — | ||
| Q1 23 | — | -54.1% | ||
| Q2 22 | — | — |
| Q2 25 | $0.02 | — | ||
| Q1 23 | — | — | ||
| Q2 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.1M | $274.8M |
| Total DebtLower is stronger | $2.9M | — |
| Stockholders' EquityBook value | $11.2M | $221.2M |
| Total Assets | $52.6M | $637.2M |
| Debt / EquityLower = less leverage | 0.26× | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $2.1M | — | ||
| Q1 23 | — | $274.8M | ||
| Q2 22 | — | $363.1M |
| Q2 25 | $2.9M | — | ||
| Q1 23 | — | — | ||
| Q2 22 | — | — |
| Q2 25 | $11.2M | — | ||
| Q1 23 | — | $221.2M | ||
| Q2 22 | — | $100.7M |
| Q2 25 | $52.6M | — | ||
| Q1 23 | — | $637.2M | ||
| Q2 22 | — | $783.1M |
| Q2 25 | 0.26× | — | ||
| Q1 23 | — | — | ||
| Q2 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-301.0K | $-26.3M |
| Free Cash FlowOCF − Capex | $-1.5M | — |
| FCF MarginFCF / Revenue | -4.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | -1.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-301.0K | — | ||
| Q1 23 | — | $-26.3M | ||
| Q2 22 | — | — |
| Q2 25 | $-1.5M | — | ||
| Q1 23 | — | — | ||
| Q2 22 | — | — |
| Q2 25 | -4.8% | — | ||
| Q1 23 | — | — | ||
| Q2 22 | — | — |
| Q2 25 | 3.8% | — | ||
| Q1 23 | — | — | ||
| Q2 22 | — | — |
| Q2 25 | -1.24× | — | ||
| Q1 23 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
